https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47517 Thu 20 Apr 2023 09:27:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10548 24 h and <8 days of age. The number of Total Serum Bilirubin tests (TSBRs) were compared for the 12 months prior (T1) with a 6-month period and 6 months after protocol introduction (T2). Transcutaneous bilirubin (TcBR) results were also collected in T2. Rates of phototherapy and peak TSBRs at commencement were also compared as measures of safety. Results: Four hundred and twenty-six of the 2197 live births in T1 required one or more TSBRs compared with 119 of the 1169 live births in T2. This represents an odds ratio of 0.47 (95% confidence interval 0.38–0.58) for infants in T2 having ≥1 TSBR compared with T1. There was no difference between the groups for rates of phototherapy (3.8% vs. 3.0%; P = 0.2) nor any difference between the groups for peak SBR during phototherapy (301.9 μmol/L (standard deviation, SD 58) for T1 vs. 303.2 μmol/L (SD 54) for T2; P = 0.45). The estimated cost saving per year is $6966.00. Conclusion: TcBR measurement in conjunction with our protocol significantly reduces painful procedures and costs without increasing the risk of delaying treatment with phototherapy.]]> Sat 24 Mar 2018 08:10:19 AEDT ]]>